Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...
Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS ...
Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have ...
Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in ...
Hims & Hers Health: Sell Rating Due to Compounding Exemption Risks and Uncertain GLP-1 Contributions
Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the price target of $18.00. Discover top-rated stocks from ...
Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...
Hims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. The personalized healthcare company -- a key player in the weight loss ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback